Alejandra Méndez Romero

TL;DR: 20 international experts including 19 members of the European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer OligoCare project developed a comprehensive system for characterisation and classification of oligometastatic disease.

TL;DR: SBRT was feasible, with acceptable toxicity and encouraging local control, and Optimal dose-fractionation schemes for HCC with cirrhosis have to be found.

TL;DR: Consensus was reached that OMD is largely independent of primary tumour, metastatic location and the presence or length of a disease-free interval, supporting both synchronous and metachronous OMD.

TL;DR: A consensus of risk-adapted SBRT fractionation was achieved with 3×15Gy for peripherally located lesions and 4×12Gy (PTV D95-D99; Dmax <125% to <150%) for lesions with broad chest wall contact, and the maximum tolerated dose of 3×18Gy should be considered.

TL;DR: A review found that RT is effective both for local ablation of focal liver metastase and for palliation of patients with symptomatic liver metastases, however, there is a lack of a high level of evidence from randomized clinical trials.